Inovalis Real Estate Investment Trust (TSE:INO) – Research analysts at National Bank Financial reduced their FY2016 EPS estimates for shares of Inovalis Real Estate Investment Trust in a research note issued to investors on Sunday. National Bank Financial analyst M. Kornack now anticipates that the brokerage will earn $0.79 per share for the year, down from their previous estimate of $0.83. National Bank Financial also issued estimates for Inovalis Real Estate Investment Trust’s FY2017 earnings at $0.82 EPS.

Earnings History and Estimates for Inovalis Real Estate Investment Trust (TSE:INO)

Inovalis Real Estate Investment Trust Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Stock Ratings for Inovalis Real Estate Investment Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalis Real Estate Investment Trust and related stocks with our FREE daily email newsletter.